PODD Stock Analysis: Insulet | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 10.186m USD | 12M Return: -54.8% | US45784P1012 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 232M
EPS Trend: 91.9%
Qual. Beats: 2
Rev. Trend: 99.8%
Qual. Beats: 17
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Insulet Corporation, headquartered in Acton, Massachusetts, develops and manufactures tubeless insulin delivery systems for people with insulin-dependent diabetes, primarily through its flagship Omnipod platform, which includes the Omnipod 5 automated insulin delivery system, the Omnipod DASH system, and the legacy Omnipod Insulin Management System. The Omnipod platform distinguishes itself from traditional tubed insulin pumps with its wearable, disposable pod design, and Insulet operates a consumable-driven recurring revenue model, as customers must continually purchase new pods. In addition to its diabetes franchise, Insulet supplies pods to Amgen for use in the Neulasta Onpro kit, a drug delivery system used to reduce infection risk following intense chemotherapy, giving the company a foothold in the broader specialty drug delivery market. The company distributes its products directly to end-users via the pharmacy channel and through independent distributors, and it is listed on NASDAQ under the ticker PODD.
- Omnipod 5 U.S. adoption accelerates automated insulin delivery growth
- GLP-1 obesity drug rise threatens type 2 insulin demand
- Drug delivery segment revenue depends on Amgen Neulasta Onpro kit
| Net Income: 375.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -1.77 > 1.0 |
| NWC/Revenue: 36.18% < 20% (prev 52.85%; Δ -16.67% < -1%) |
| CFO/TA 0.16 > 3% & CFO 511.2m > Net Income 375.3m |
| Net Debt (418.1m) to EBITDA (471.7m): 0.89 < 3 |
| Current Ratio: 2.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.4m) vs 12m ago -1.75% < -2% |
| Gross Margin: 71.08% > 18% (prev 70.74%; Δ 0.34% > 0.5%) |
| Asset Turnover: 92.05% > 50% (prev 68.01%; Δ 24.04% > 0%) |
| Interest Coverage Ratio: 6.61 > 6 (EBIT TTM 419.1m / Interest Expense TTM 63.4m) |
| A: 0.35 (Total Current Assets 1.85b - Total Current Liabilities 744.2m) / Total Assets 3.17b |
| B: 0.15 (Retained Earnings 473.5m / Total Assets 3.17b) |
| C: 0.13 (EBIT TTM 419.1m / Avg Total Assets 3.32b) |
| D: 0.82 (Book Value of Equity 1.42b / Total Liabilities 1.74b) |
| Altman-Z'' = 4.48 = AA |
| DSRI: 1.02 (Receivables 588.7m/444.5m, Revenue 3.05b/2.36b) |
| GMI: 1.00 (GM 70.74% / 71.08%) |
| AQI: 1.02 (AQ_t 0.14 / AQ_t-1 0.14) |
| SGI: 1.29 (Revenue 3.05b / 2.36b) |
| TATA: -0.04 (NI 375.3m - CFO 511.2m) / TA 3.17b) |
| Beneish M = -2.79 (Cap -4..+1) = A |
As of August 22, 2026, the stock is trading at USD 148.16 with a total of 878,513 shares traded. Over the past week, the price has changed by +3.36%, over one month by -9.50%, over three months by -5.56% and over the past year by -54.81%.
Current recommended Stop Loss: 133.50 (which is 9.9% or 2 ATR below the current price).
Insulet has received a consensus analysts rating of 4.58. Therefore, it is recommended to buy PODD.
- StrongBuy: 17
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 171.9 | 16% |
P/E Trailing = 28.4081
P/E Forward = 25.0
P/S = 3.336
P/B = 7.3841
P/EG = 1.5215
Revenue TTM = 3.05b USD
EBIT TTM = 419.1m USD
EBITDA TTM = 471.7m USD
Long Term Debt = 929.5m USD (from longTermDebt, last quarter)
Short Term Debt = 18.9m USD (from shortTermDebt, last quarter)
Debt = 953.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.60m
Net Debt = 418.1m USD (calculated: Debt 953.0m - CCE 534.9m)
Enterprise Value = 10.6b USD (10.2b + Debt 953.0m - CCE 534.9m)
Interest Coverage Ratio = 6.61 (Ebit TTM 419.1m / Interest Expense TTM 63.4m)
EV/FCF = 35.55x (Enterprise Value 10.6b / FCF TTM 298.3m)
FCF Yield = 2.81% (FCF TTM 298.3m / Enterprise Value 10.6b)
FCF Margin = 9.77% (FCF TTM 298.3m / Revenue TTM 3.05b)
Net Margin = 12.29% (Net Income TTM 375.3m / Revenue TTM 3.05b)
Gross Margin = 71.08% ((Revenue TTM 3.05b - Cost of Revenue TTM 883.1m) / Revenue TTM)
Gross Margin QoQ = 70.18% (prev 69.46%)
Tobins Q-Ratio = 3.35 (Enterprise Value 10.6b / Total Assets 3.17b)
Interest Expense / Debt = 6.65% (Interest Expense 63.4m / Debt 953.0m)
Taxrate = 24.12% (119.3m / 494.7m)
NOPAT = 318.0m (EBIT 419.1m * (1 - 24.12%))
Current Ratio = 2.48 (Total Current Assets 1.85b / Total Current Liabilities 744.2m)
Debt / Equity = 0.67 (Debt 953.0m / totalStockholderEquity, last quarter 1.42b)
Debt / EBITDA = 0.89 (Net Debt 418.1m / EBITDA 471.7m)
Debt / FCF = 1.40 (Net Debt 418.1m / FCF TTM 298.3m)
Total Stockholder Equity = 1.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.31% (Net Income 375.3m / Total Assets 3.17b)
RoE = 26.69% (Net Income TTM 375.3m / Total Stockholder Equity 1.41b)
RoCE = 17.94% (EBIT 419.1m / Capital Employed (Equity 1.41b + L.T.Debt 929.5m))
RoIC = 13.91% (NOPAT 318.0m / Invested Capital 2.29b)
WACC = 6.39% (E(10.2b)/V(11.1b) * Re(6.52%) + D(953.0m)/V(11.1b) * Rd(6.65%) * (1-Tc(0.24)))
Discount Rate = 6.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -88.98 | Cagr: -2.66%
[DCF] Terminal Value 73.10% ; FCFF base≈334.3m ; Y1≈293.2m ; Y5≈236.9m
[DCF] Fair Price = 48.79 (EV 3.80b - Net Debt 418.1m = Equity 3.38b / Shares 69.4m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 91.88 | EPS CAGR: 43.58% | SUE: 2.45 | # QB: 2
Revenue Correlation: 99.82 | Revenue CAGR: 27.26% | SUE: 2.09 | # QB: 17
EPS current Quarter (2026-09-30): EPS=1.59 | Chg30d=-3.04% | Revisions=-59% | Analysts=21
EPS current Year (2026-12-31): EPS=6.50 | Chg30d=+0.44% | Revisions=+38% | GrowthEPS=+30.8% | GrowthRev=+21.4%
EPS next Year (2027-12-31): EPS=7.71 | Chg30d=-4.24% | Revisions=-79% | GrowthEPS=+18.6% | GrowthRev=+13.9%
[Analyst] Revisions Ratio: -36% (up=19, down=42)